Anna Kanerva

6.8k citations

125 papers · 4.7k indexed · h-index 39

Impact in

Genetics top 0.2%
- Virus-based gene therapy research
Biotechnology top 0.2%
- Cancer Research and Treatments

Papers in ⓘ

Genetics 118
- Virus-based gene therapy research 115
Biotechnology 31
- Cancer Research and Treatments 31

Co-authors: Akseli Hemminki (118 shared papers)David T. Curiel (19 shared papers)Gerd Bauerschmitz (23 shared papers)Vincenzo Cerullo (26 shared papers)Ronald D. Alvarez (10 shared papers)Tanja Hakkarainen (17 shared papers)Merja Särkioja (17 shared papers)Riikka Havunen (27 shared papers)
Journals: Molecular Therapy (19 papers)International Journal of Cancer (11 papers)Gene Therapy (10 papers)OncoImmunology (8 papers)Cancer Gene Therapy (7 papers)
Partner nations: Finland United States Germany

In The Last Decade

Anna Kanerva

120 papers receiving 4.6k citations

Peers

Countries citing papers authored by Anna Kanerva

Since Specialization

Citations

This map shows the geographic impact of Anna Kanerva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Kanerva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Kanerva more than expected).

Fields of papers citing papers by Anna Kanerva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Kanerva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Kanerva. The network helps show where Anna Kanerva may publish in the future.

Co-authors

The 25 scholars most cited alongside Anna Kanerva, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anna Kanerva Line = papers co-authored together Anna Kanerva links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 125 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. PubMed ·Anna Kanerva, Galina Mikheeva, Victor Krasnykh, Candace J. Coolidge, John Lam, Parameshwar J. Mahasreshti, Shannon Barker, Michael J. Straughn, Mack N. Barnes, Ronald D. Alvarez, Akseli Hemminki, David T. Curiel	2002	208
2	Gene Transfer to Ovarian Cancer Versus Normal Tissues with Fiber-Modified Adenoviruses Molecular Therapy ·Anna Kanerva, Minghui Wang, Gerd Bauerschmitz, John Lam, Renée A. Desmond, Snehal M. Bhoola, Mack N. Barnes, Ronald D. Alvarez, Gene P. Siegal, David T. Curiel, Akseli Hemminki	2002	156
3	Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus Clinical Cancer Research ·Anna Kanerva, Petri Nokisalmi, Iulia Diaconu, Anniina Koski, Vincenzo Cerullo, Ilkka Liikanen, Siri Tähtinen, Minna Oksanen, Raita Heiskanen, Saila K. Pesonen, Timo Joensuu, Tuomo Alanko, Kaarina Partanen, Leena Laasonen, Kalevi Kairemo, Sari Pesonen, Lotta Kangasniemi, Akseli Hemminki	2013	144
4	Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus Molecular Therapy ·Anna Kanerva, Kurt R. Zinn, Tandra R. Chaudhuri, John Lam, Kaori Suzuki, Taco G. Uil, Tanja Hakkarainen, Gerd Bauerschmitz, Minghui Wang, Bin Liu, Zhihong Cao, Ronald D. Alvarez, David T. Curiel, Akseli Hemminki	2003	143
5	Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients Molecular Therapy ·Ilkka Liikanen, Laura Ahtiainen, Mari Hirvinen, Simona Bramante, Vincenzo Cerullo, Petri Nokisalmi, Otto Hemminki, Iulia Diaconu, Sari Pesonen, Anniina Koski, Lotta Kangasniemi, Saila K. Pesonen, Minna Oksanen, Leena Laasonen, Kaarina Partanen, Timo Joensuu, Fang Zhao, Anna Kanerva, Akseli Hemminki	2013	139
6	Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. PubMed ·Gerd Bauerschmitz, John Lam, Anna Kanerva, Kaori Suzuki, Dirk M. Nettelbeck, Igor P. Dmitriev, Victor Krasnykh, Galina Mikheeva, Mack N. Barnes, Ronald D. Alvarez, Peter Dall, Ramón Alemany, David T. Curiel, Akseli Hemminki	2002	130
7	Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4 Gene Therapy ·João D. Dias, Otto Hemminki, Ioan Diaconu, Mari Hirvinen, Alessandro Bonetti, Kilian Guse, Sophie Escutenaire, Anna Kanerva, Saila K. Pesonen, Angelica Loskog, Vincenzo Cerullo, Akseli Hemminki	2011	128
8	Human Mesenchymal Stem Cells Lack Tumor Tropism but Enhance the Antitumor Activity of Oncolytic Adenoviruses in Orthotopic Lung and Breast Tumors Human Gene Therapy ·Tanja Hakkarainen, Merja Särkioja, Petri Lehenkari, Susanna Miettinen, Timo Ylikomi, Riitta Suuronen, Renée A. Desmond, Anna Kanerva, Akseli Hemminki	2007	117
9	Modified adenoviruses for cancer gene therapy International Journal of Cancer ·Anna Kanerva, Akseli Hemminki	2004	111
10	Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients Cancer Research ·Sari Pesonen, Iulia Diaconu, Lotta Kangasniemi, Tuuli Ranki, Anna Kanerva, Saila K. Pesonen, Ulrike Gerdemann, Ann M. Leen, Kalevi Kairemo, Minna Oksanen, Elina Haavisto, Liisa Holm, Aila Karioja‐Kallio, Satu Kauppinen, Kaarina Partanen, Leena Laasonen, Tima Joensuu, Tuomo Alanko, Vincenzo Cerullo, Akseli Hemminki	2012	107
11	Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy Molecular Therapy — Oncolytics ·Riikka Havunen, Mikko Siurala, Suvi Sorsa, Susanna Grönberg-Vähä-Koskela, Michaël Behr, Siri Tähtinen, João M. Santos, Pauliina Karell, Juuso Rusanen, Dirk M. Nettelbeck, Anja Ehrhardt, Anna Kanerva, Akseli Hemminki	2017	103
12	TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade OncoImmunology ·Víctor Cervera-Carrascón, Mikko Siurala, João M. Santos, Riikka Havunen, Siri Tähtinen, Pauliina Karell, Suvi Sorsa, Anna Kanerva, Akseli Hemminki	2018	90
13	Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. PubMed ·Akseli Hemminki, Anna Kanerva, Bin Liu, Minghui Wang, Ronald D. Alvarez, Gene P. Siegal, David T. Curiel	2003	89
14	1364. Adenoviral Gene Therapy for Renal Cancer Requires Retargeting to Alternative Cellular Receptors Molecular Therapy ·Yosef S. Haviv, Jerry L. Blackwell, Anna Kanerva, Peter A. Nagi, Victor Krasnykh, Igor P. Dmitriev, Minghui Wang, Seiji Naito, Xiaosheng Lei, Akseli Hemminki, Delicia Carey, David T. Curiel	2002	85
15	Oncolytic Adenoviruses Kill Breast Cancer Initiating CD44+CD24–/Low Cells Molecular Therapy ·Minna Eriksson, Kilian Guse, Gerd Bauerschmitz, Pekka Virkkunen, Maija Tarkkanen, Minna Tanner, Tanja Hakkarainen, Anna Kanerva, Renée A. Desmond, Sari Pesonen, Akseli Hemminki	2007	83
16	A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model Molecular Therapy ·Akseli Hemminki, Anna Kanerva, Eric J. Kremer, Gerd Bauerschmitz, B. F. Smith, Bin Liu, Minghui Wang, Renée A. Desmond, Anne Keriel, Brian Barnett, Henry J. Baker, Gene P. Siegal, David T. Curiel	2003	83
17	Tissue-Specific Promoters Active in CD44+CD24−/low Breast Cancer Cells Cancer Research ·Gerd Bauerschmitz, Tuuli Ranki, Lotta Kangasniemi, Camilla Ribacka, Minna Eriksson, Marius Porten, Isabell Herrmann, Ari Ristimäki, Pekka Virkkunen, Maija Tarkkanen, Tanja Hakkarainen, Anna Kanerva, Daniel Rein, Sari Pesonen, Akseli Hemminki	2008	83
18	An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance Molecular Therapy ·Vincenzo Cerullo, Iulia Diaconu, Valentina Romano, Mari Hirvinen, Matteo Ugolini, Sophie Escutenaire, Liisa Holm, Anja Kipar, Anna Kanerva, Akseli Hemminki	2012	81
19	Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy Oncotarget ·Otto Hemminki, Suvi Parviainen, Juuso Juhila, Riku Turkki, Nina Linder, Johan Lundin, Matti Kankainen, Ari Ristimäki, Anniina Koski, Ilkka Liikanen, Minna Oksanen, Dirk M. Nettelbeck, Kalevi Kairemo, Kaarina Partanen, Timo Joensuu, Anna Kanerva, Akseli Hemminki	2015	69
20	Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer Gene Therapy ·Mari Raki, Anna Kanerva, Ari Ristimäki, R A Desmond, D-T Chen, Tuuli Ranki, Merja Särkioja, Lotta Kangasniemi, Akseli Hemminki	2005	68

About Anna Kanerva

Anna Kanerva is a scholar working on Genetics, Biotechnology, Oncology, Molecular Biology and Immunology, having authored 125 papers that have together received 4.7k indexed citations. Recurring topics across this work include Virus-based gene therapy research (115 papers), CAR-T cell therapy research (90 papers), Viral Infectious Diseases and Gene Expression in Insects (43 papers), Cancer Research and Treatments (31 papers), RNA Interference and Gene Delivery (20 papers), Immunotherapy and Immune Responses (18 papers), Viral gastroenteritis research and epidemiology (9 papers) and CRISPR and Genetic Engineering (5 papers). The work is most often cited by research in Genetics (3.8k citations), Biotechnology (995 citations), Oncology (3.1k citations), Molecular Biology (2.5k citations) and Immunology (695 citations). Anna Kanerva has collaborated with scholars based in Finland, United States and Germany. Frequent co-authors include Akseli Hemminki, David T. Curiel, Gerd Bauerschmitz, Vincenzo Cerullo, Ronald D. Alvarez, Tanja Hakkarainen, Merja Särkioja, Riikka Havunen, Lotta Kangasniemi and Minghui Wang. Their work appears in journals such as Molecular Therapy, International Journal of Cancer, Gene Therapy, OncoImmunology and Cancer Gene Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact